Results 111 to 120 of about 56,599 (248)

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study

, 2013
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital, Prato, ItalyBackground: The aim of this study was to evaluate the proportion of patients with ankylosing ...
Niccoli L, Cantini F, Cassara E, Kaloudi O, Nannini C   +4 more
core  

Etanercept for the treatment of rheumatoid arthritis.

, 2013
BACKGROUND: Etanercept is a soluble tumour necrosis factor alpha-receptor disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).
Lethaby, A, Maxwell, L, Burls, A, Tugwell, P, Lopez-Olivo, MA, Burls, Amanda, Wells, GA   +6 more
core   +1 more source

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis

Practical Laboratory Medicine, 2019
Objective: Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was
Nicole Yang, Jie Huang, Michelle Frits, Christine Iannaccone, Michael E. Weinblatt, Nader Rifai, Nancy Shadick, Gary Bradwin, Katherine P. Liao   +8 more
doaj   +1 more source

The evolving role of regulatory T cells in Sjögren's disease pathogenesis and the promise of Treg‐based therapies: A comprehensive review

Rheumatology &Autoimmunity, EarlyView.
Graphical Abstract The evolving role of regulatory T cells in primary Sjögren's disease pathogenesis and the promise of Treg‐based therapies. Abstract Sjögren's disease (SjD) is a chronic systemic autoimmune disorder characterised by exocrine gland dysfunction and diverse systemic manifestations.
Gagan Urs, Bharath Raj Srinivasan, Himabindu Jayaprakash Narayan, Mirunalini Gobinath, Lekitha Manjunath, Mahabaleshwar Mamadapur   +5 more
wiley   +1 more source

Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment

, 2017
Aim: Etanercept has shown to mediate a favorable effect on immune-mediated inflammatory diseases (IMID), including plaque psoriasis. Therapeutic drug monitoring (TDM) of etanercept could improve clinical outcome and cost-effectiveness.
Koch, Birgit C. P., Prens, Errol P., van Bezooijen, Ji S., te Velthuis, Henk, van Doorn, Martijn B. A., Schreurs, Marco W. J., van Gelder, Teun   +6 more
core   +1 more source

Etanercept - Can It be Used in the Treatment of Endotoxemia? [PDF]

, 2013
Aim of this study was to investigate that effect of etanercept administration on the concentrations of cytokines, fibrinogen, antithrombin, 13,14-dihydro-15-keto-prostaglandin F-2 alpha and biochemical values in the endotoxemia.
Altan, FERAY, Er, Ayse, Dik, Burak, Yazar, Enver, Elmas, Muammer, Cetin, Gul, Uney, Kamil   +6 more
core   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara, Tanja Tran, Sandeep Kiri, Romy Bley, Kathrin Schlüter, Claudia Grellmann, Sima Melnik, Sylke Schneider‐Burrus   +7 more
wiley   +1 more source

Etanercept Enhances Preservation of Osteochondral Allograft Viability

, 2011
Background: Osteochondral allografts are an increasingly popular treatment for the repair of articular cartilage lesions. Current tissue bank protocols require bacteriological testing that takes from 21 to 28 days to process.
William D. Bugbee, Robert M. Healey, David Amiel, Michael S. Linn, Frederick L. Harwood, Derek C. Chase   +5 more
core   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source